RxDoctor Payments Data

Roberto Beaton, MD

Internal Medicine · Burbank, CANPI 1669550885

Payments from drug & device makers

$1,264in general payments, 2019–2025

Across 67 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$276
  • Sanofi-aventis U.S. LLC$151
  • Astellas Pharma US Inc$147
  • Amgen$128
  • Novo Nordisk$127
  • Novartis$112
  • plus $324 from 13 others

What the payments were for

  • Food & beverage$1,258100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,264 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$344,262
Medicare patients
341
Services billed
4,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate163$122,023
FarxigaDapagliflozin Propanediol121$99,140
Metformin Er GastricMetformin Hcl76$96,967
ProliaDenosumab56$93,744
EliquisApixaban169$86,767
LinzessLinaclotide125$83,699
XareltoRivaroxaban81$59,995
TrulicityDulaglutide60$58,876
JardianceEmpagliflozin72$54,411
OzempicSemaglutide49$46,094
Diclofenac Sodium160$36,713
VascepaIcosapent Ethyl68$28,336
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog96$25,590
Pitavastatin Calcium120$23,484
TradjentaLinagliptin32$17,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$122,023163 claims
AstraZenecaFarxiga$276$99,140121 claims
AmgenProlia$128$93,74456 claims
PfizerEliquis, Premarin$29$91,783184 claims
Boehringer IngelheimJardiance, Tradjenta$16$71,426104 claims
Johnson & JohnsonXarelto$16$59,99581 claims
Lilly USA, LLCTrulicity$59$58,87660 claims
Novo NordiskOzempic, Rybelsus$127$57,42761 claims
GSKTrelegy Ellipta, Breo Ellipta$44$18,72636 claims
Astellas Pharma US IncMyrbetriq$147$12,46422 claims
NovartisEntresto$112$8,12612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →